Interruption of selective serotonin reuptake inhibitor treatment - Double-blind, placebo-controlled trial
Interruption of selective serotonin reuptake inhibitor treatment - Double-blind, placebo-controlled trial
复制标题
DOI：
10.1192/bjp.176.4.363
复制
发表时间：
2000-04-01
影响因子：
10.5
通讯作者：
Tepner, RG
中科院分区：
文献类型：
--
作者：
Michelson, D;Fava, M;Tepner, RG
背景：突然中断选择性血清素再摄取抑制剂（SSRIs）治疗与躯体和心理症状有关。目的系统评估SSRI治疗中断后的症状和对日常功能的影响。方法采用氟西汀、舍曲林或帕罗西汀治疗的患者在双盲随机条件下接受相同的5天治疗中断和继续积极治疗，定期评估新症状。结果安慰剂替代帕罗西汀与第二次错过剂量后不良事件的数量和严重程度增加有关，并且在第5天功能损害增加。安慰剂替代舍曲林导致的变化不太明显，而氟西汀的中断与症状的任何显著增加无关。结论突然中断SSRI治疗可导致以特定生理和心理症状为特征的综合征。ssri类药物的发生率、时间和症状严重程度各不相同，似乎与血浆消除特性有关。本研究由礼来公司赞助。
Background Abrupt interruption of therapy with selective serotonin reuptake inhibitors (SSRIs) has been associated with somatic and psychological symptoms.Aims Systematically to assess symptoms and effects on daily functioning related to interruption of SSRI therapy.Method Patients treated with fluoxetine, setraline or paroxetine underwent identical five-day periods of treatment interruption and continued active treatment under double-blind order-randomised conditions, with regular assessment of new symptoms.Results Placebo substitution for paroxetine was associated with increases in the number and severity of adverse events following the second missed dose, and increases in functional impairment at five days. Placebo substitution for sertraline resulted in less pronounced changes, while interruption of fluoxetine was not associated with any significant increase in symptomatology.Conclusions Abrupt interruption of SSRI treatment can result in a syndrome characterised by specific physical and psychological symptoms. Incidence, timing and severity of symptoms vary among SSRIs in a fashion that appears to be related to plasma elimination characteristics.Declaration of interest This work was sponsored by Eli Lilly and Company.